April 30 Clinical Quick Takes: Xencor, Axovant, Cell Medica
Partial hold lifted on Xencor's blood cancer bispecific
FDA lifted a partial clinical hold on a Phase I trial of XmAb14045 from Xencor Inc. (NASDAQ:XNCR), which is evaluating the bispecific antibody against CD3 and CD123 to treat relapsed or refractory acute myelogenous leukemia (AML) and other CD123-expressing hematologic malignancies (see "Partial Hold for Phase I of Xencor's Blood Cancer Bispecific").
Axovant doses patient with Parkinson’s gene therapy
The first patient who received Parkinson's disease gene therapy AXO-Lenti-PD from Axovant Gene Therapies Ltd. (NASDAQ:AXGT) in the Phase II SUNRISE-PD trial’s second cohort experienced no complications related to the surgery or administration of the vector. Initial data are expected in 4Q19. The cohort’s start triggered a $15 million milestone payment to Oxford BioMedica plc (LSE:OXB) (see "Axovant Reports First Clinical Gene Therapy Data")...